Glutamine Supplementation in Sick Children: Is It Beneficial?
The purpose of this review is to provide a critical appraisal of the literature on Glutamine (Gln) supplementation in various conditions or illnesses that affect children, from neonates to adolescents. First, a general overview of the proposed mechanisms for the beneficial effects of Gln is provided...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228321/ |
| id |
pubmed-3228321 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-32283212011-12-15 Glutamine Supplementation in Sick Children: Is It Beneficial? Mok, Elise Hankard, Régis Review Article The purpose of this review is to provide a critical appraisal of the literature on Glutamine (Gln) supplementation in various conditions or illnesses that affect children, from neonates to adolescents. First, a general overview of the proposed mechanisms for the beneficial effects of Gln is provided, and subsequently clinical studies are discussed. Despite safety, studies are conflicting, partly due to different effects of enteral and parenteral Gln supplementation. Further insufficient evidence is available on the benefits of Gln supplementation in pediatric patients. This includes premature infants, infants with gastrointestinal disease, children with Crohn's disease, short bowel syndrome, malnutrition/diarrhea, cancer, severe burns/trauma, Duchenne muscular dystrophy, sickle cell anemia, cystic fibrosis, and type 1 diabetes. Moreover, methodological issues have been noted in some studies. Further mechanistic data is needed along with large randomized controlled trials in select populations of sick children, who may eventually benefit from supplemental Gln. Hindawi Publishing Corporation 2011 2011-11-14 /pmc/articles/PMC3228321/ /pubmed/22175008 http://dx.doi.org/10.1155/2011/617597 Text en Copyright © 2011 E. Mok and R. Hankard. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Mok, Elise Hankard, Régis |
| spellingShingle |
Mok, Elise Hankard, Régis Glutamine Supplementation in Sick Children: Is It Beneficial? |
| author_facet |
Mok, Elise Hankard, Régis |
| author_sort |
Mok, Elise |
| title |
Glutamine Supplementation in Sick Children: Is It Beneficial? |
| title_short |
Glutamine Supplementation in Sick Children: Is It Beneficial? |
| title_full |
Glutamine Supplementation in Sick Children: Is It Beneficial? |
| title_fullStr |
Glutamine Supplementation in Sick Children: Is It Beneficial? |
| title_full_unstemmed |
Glutamine Supplementation in Sick Children: Is It Beneficial? |
| title_sort |
glutamine supplementation in sick children: is it beneficial? |
| description |
The purpose of this review is to provide a critical appraisal of the literature on Glutamine (Gln) supplementation in various conditions or illnesses that affect children, from neonates to adolescents. First, a general overview of the proposed mechanisms for the beneficial effects of Gln is provided, and subsequently clinical studies are discussed. Despite safety, studies are conflicting, partly due to different effects of enteral and parenteral Gln supplementation. Further insufficient evidence is available on the benefits of Gln supplementation in pediatric patients. This includes premature infants, infants with gastrointestinal disease, children with Crohn's disease, short bowel syndrome, malnutrition/diarrhea, cancer, severe burns/trauma, Duchenne muscular dystrophy, sickle cell anemia, cystic fibrosis, and type 1 diabetes. Moreover, methodological issues have been noted in some studies. Further mechanistic data is needed along with large randomized controlled trials in select populations of sick children, who may eventually benefit from supplemental Gln. |
| publisher |
Hindawi Publishing Corporation |
| publishDate |
2011 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228321/ |
| _version_ |
1611491160184848384 |